Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children

Rhabdomyosarcoma, Child Clinical Trial

Official title: Efficacy and Safety of Concurrent Radiotherapy With Realgar-Indigo Naturalis Formula in the Treatment of Childhood Rhabdomyosarcoma

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial]is to evaluate the efficacy, safety and feasibility of radiotherapy combined with Realgar-Indigo naturalis formula（An oral arsenic agent）in the treatment of rhabdomyosarcoma in children. Including the occurrence of adverse events and the improvement of quality of life.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Rhabdomyosarcoma

• NCT number: NCT05708391
• Study type: Interventional
• Source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: SiYu Chen, Dr
• Phone: 0086-13651687212
• Email: siyu.chen@shsmu.edu.cn
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 31, 2023
• Completion date: December 30, 2024